Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Lescarden Inc is a biotechnology company. It is engaged in the research, testing, and development of medications for the control and cure of various diseases and the licensing of its technologies for commercialization by other companies. Its lead product is Catrix Wound Dressing for the management of chronic lesions and burns, as well as for non-healing wounds, including decubitus ulcers, venous stasis ulcers, and diabetic ulcers. In addition, the group is also involved in the line of Catrix-based skin care products targeting the plastic surgery, dermatology and medical spa markets. Geographically, the business presence of the firm is seen in the regions of United States, Europe, and South Korea.
New York, NY, 10170